← Live StudiesRegistry: recruitingPhase 3

MARITIME-SWITCH: Switching GLP-1 medicines

Looks at efficacy, safety and tolerability when adults who have lost weight on a weekly GLP-1 medicine switch to investigational maridebart cafraglutide.

Who it's for

  • Age 18+
  • Already using a stable weekly GLP-1 medicine with prior weight loss
  • Diabetes excluded

Full eligibility rules apply. The study team decides who can take part.

Where it runs

9 research locations in Arizona, California and Hawaii.

Arizona

  • Arizona Clinical TrialsChandler, AZ
  • Epic Medical Research - Sun CitySun City, AZ
  • Clinical Research Institute of Arizona LLCSun City West, AZ

California

  • Desert Oasis Healthcare Medical GroupPalm Springs, CA
  • Inland Empire Liver FoundationRialto, CA
  • Peninsula Research AssociatesRolling Hills Estates, CA
  • Apex Clinical ResearchSan Diego, CA
  • Southern California Clinical ResearchSanta Ana, CA

Hawaii

  • Mel A. Ona, M.D., IncorporatedKapolei, HI

Site recruitment may change. The official record lists every location, including outside these states.

Interested in this study?

Ask us about it, or refer a patient. Taking part is voluntary, and the study team decides who can join.